Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Chang Liu(Centre for Human Genetics), Helen M. Ginn(Diamond Light Source), Wanwisa Dejnirattisai(Centre for Human Genetics), Piyada Supasa(Centre for Human Genetics), Beibei Wang(Centre for Human Genetics), Aekkachai Tuekprakhon(Centre for Human Genetics), Rungtiwa Nutalai(Centre for Human Genetics), Daming Zhou(Centre for Human Genetics), Alexander J. Mentzer(Centre for Human Genetics), Yuguang Zhao(Centre for Human Genetics), Helen M. E. Duyvesteyn(Centre for Human Genetics), César López‐Camacho(Centre for Human Genetics), Jose Slon-Campos(Centre for Human Genetics), Thomas S. Walter(Centre for Human Genetics), Donal Skelly(University of Oxford), Síle A. Johnson(Medawar Building for Pathogen Research), Thomas Ritter(Oxford University Hospitals NHS Trust), Chris Mason(Oxford University Hospitals NHS Trust), Sue Ann Costa Clemens(University of Siena), Felipe Gomes Naveca, Valdinete Alves do Nascimento, Fernanda Nascimento, Cristiano Fernandes da Costa(Fundação de Medicina Tropical), Paola Cristina Resende(Fundação Oswaldo Cruz), Alex Pauvolid‐Corrêa(Fundação Oswaldo Cruz), Marilda Mendonça Siqueira(Fundação Oswaldo Cruz), Christina Dold(University of Oxford), Nigel Temperton(Medway School of Pharmacy), Tao Dong(University of Oxford), Andrew J. Pollard(University of Oxford), Julian C. Knight(Centre for Human Genetics), Derrick W. Crook(University of Oxford), Teresa Lambe(University of Oxford), Elizabeth Clutterbuck(University of Oxford), Sagida Bibi(University of Oxford), Amy Flaxman(University of Oxford), Mustapha Bittaye(University of Oxford), Sandra Belij‐Rammerstorfer(University of Oxford), Sarah C. Gilbert(University of Oxford), Tariq Malik(Public Health England), Miles W. Carroll(Centre for Human Genetics), Paul Klenerman(University of Oxford), Eleanor Barnes(University of Oxford), Susanna Dunachie(Angkor Hospital for Children), Vicky L. Baillie(South African Medical Research Council), Natali Serafin(South African Medical Research Council), Zanele Ditse(South African Medical Research Council), Kelly da Silva(South African Medical Research Council), Neil G. Paterson(Diamond Light Source), Mark A. Williams(Diamond Light Source), David R. Hall(Diamond Light Source), Shabir A. Madhi(South African Medical Research Council), Marta C. Nunes(South African Medical Research Council), Philip Goulder(University of Oxford), Elizabeth E. Fry(Centre for Human Genetics), Juthathip Mongkolsapaya(Siriraj Hospital), Jingshan Ren(Centre for Human Genetics), David I. Stuart(Centre for Human Genetics), Gavin Screaton(Centre for Human Genetics)
Cell
June 17, 2021
10.1016/j.cell.2021.06.020
Cited by 747Open Access
Full Text

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive change, with variants conferring advantage rapidly becoming dominant lineages, e.g., B.1.617. With apparent increased transmissibility, variant B.1.617.2 has contributed to the current wave of infection ravaging the Indian subcontinent and has been designated a variant of concern in the United Kingdom. Here we study the ability of monoclonal antibodies and convalescent and vaccine sera to neutralize B.1.617.1 and B.1.617.2, complement this with structural analyses of Fab/receptor binding domain (RBD) complexes, and map the antigenic space of current variants. Neutralization of both viruses is reduced compared with ancestral Wuhan-related strains, but there is no evidence of widespread antibody escape as seen with B.1.351. However, B.1.351 and P.1 sera showed markedly more reduction in neutralization of B.1.617.2, suggesting that individuals infected previously by these variants may be more susceptible to reinfection by B.1.617.2. This observation provides important new insights for immunization policy with future variant vaccines in non-immune populations.

Related Papers

No related papers found

Powered by citation graph analysis